Harbourvest Partners’s CytomX Therapeutics CTMX Stock Holding History

Harbourvest Partners’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-79,193	Closed	-$343K	–	68
2021 Q4	$343K	Hold	79,193	–	–	0.04%	54
2021 Q3	$403K	Hold	79,193	–	–	0.04%	46
2021 Q2	$501K	Hold	79,193	–	–	0.05%	38
2021 Q1	$612K	Hold	79,193	–	–	0.08%	29
2020 Q4	$519K	Hold	79,193	–	–	0.2%	17
2020 Q3	$527K	Hold	79,193	–	–	0.2%	24
2020 Q2	$660K	Hold	79,193	–	–	0.28%	19
2020 Q1	$607K	Hold	79,193	–	–	0.29%	25
2019 Q4	$658K	Hold	79,193	–	–	0.27%	25
2019 Q3	$584K	Hold	79,193	–	–	0.24%	21
2019 Q2	$889K	Hold	79,193	–	–	0.33%	21
2019 Q1	$851K	Hold	79,193	–	–	0.3%	21
2018 Q4	$1.2M	Hold	79,193	–	–	0.57%	18
2018 Q3	$1.43M	Hold	79,193	–	–	1.29%	12
2018 Q2	$1.81M	Buy	+79,193	New	+$2.02M	2.29%	10
2017 Q3	–	Sell	-39,199	Closed	-$608K	–	23
2017 Q2	$608K	Buy	39,199 +14,199	+57%	+$214K	0.26%	14
2017 Q1	$432K	Buy	25,000 +15,000	+150%	+$197K	0.24%	14
2016 Q4	$110K	Buy	+10,000	New	+$121K	0.07%	16
2016 Q3	–	Sell	-10,000	Closed	-$102K	–	12
2016 Q2	$102K	Buy	+10,000	New	+$114K	0.05%	20

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Harbourvest Partners's CTMX Position: Q1 2022 in Review

Harbourvest Partners sold out of CytomX Therapeutics (CTMX) in Q1 2022, closing a stake of 79,193 shares — an estimated $343K sold.

Harbourvest Partners first reported a position in CTMX in Q2 2016 and held it in 19 quarters. The position peaked at $1.81M in Q2 2018. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

Harbourvest Partners reported no remaining CytomX Therapeutics position as of Q1 2022 after selling out during the quarter.
Harbourvest Partners sold 79,193 CytomX Therapeutics shares in Q1 2022, an estimated $343K.
Harbourvest Partners first reported a position in CytomX Therapeutics in Q2 2016 and held it in 19 quarters.
Harbourvest Partners's CytomX Therapeutics position peaked at $1.81M in Q2 2018.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Harbourvest Partners's 13F filing for Q1 2022, filed 13 May 2022.